Skip to main content
REGENA PEPTIDES

Research Library

TZ Research: Dual GIP/GLP-1 Agonism Evidence

TZ is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and for chronic weight management in several jurisdictions. It has the most complete trial dataset of the current multi-receptor agents.

Summary

TZ is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and for chronic weight management in several jurisdictions. It has the most complete trial dataset of the current multi-receptor agents.

Last reviewed 2026-09-01

What it is

TZ is a 39–amino-acid synthetic peptide based on the native GIP sequence, modified with a C20 fatty diacid for albumin binding and once-weekly dosing, and engineered to activate both the GIP and GLP-1 receptors.

First described in the published literature in the late 2010s; it is the subject of a large body of peer-reviewed research.

Synthetic; the backbone is GIP-derived rather than GLP-1-derived, which distinguishes it from earlier agents.

It demonstrated that GIP receptor activity added to GLP-1 activity produces greater weight and glycaemic effects than GLP-1 alone — reversing an earlier assumption that GIP antagonism would be the useful direction.

How it works

In plain terms

It acts on two gut-hormone systems at once. Together they reduce appetite, slow how quickly the stomach empties and improve how the body handles glucose more than either does alone.

Technical detail

TZ is an imbalanced agonist with greater potency at GIPR than GLP-1R relative to the native hormones. GLP-1R activation drives satiety signalling in the hypothalamus and area postrema, slows gastric emptying and enhances glucose-dependent insulin secretion while suppressing glucagon. GIPR activation adds insulinotropic effect, appears to improve adipose tissue insulin sensitivity and lipid buffering, and may reduce the nausea burden associated with GLP-1 activation through central GIPR signalling.

Pathways involved

  • GLP-1R: satiety, gastric emptying, insulin secretion
  • GIPR: insulinotropic effect, adipose insulin sensitivity
  • Combined hypothalamic and hindbrain appetite regulation
  • Albumin-bound weekly pharmacokinetics

Current research

Laboratory research

Receptor assays confirmed the imbalanced dual-agonist profile; adipocyte studies support a GIP-mediated role in lipid handling.

Animal research

Rodent studies showed additive weight and glycaemic effects over GLP-1 mono-agonism at matched exposure.

Human research

The sleep-apnoea trial reported large reductions in apnoea–hypopnoea index. The HFpEF trial reported benefit in heart failure with preserved ejection fraction and obesity. Cardiovascular outcome data from its cardiovascular outcomes trial has been reported as non-inferior to dulaglutide.

Ongoing research

Long-term outcome and comparative-effectiveness programmes continue across metabolic and cardiovascular indications.

What is being investigated

  • Glycaemic control in type 2 diabetes (approved indication)
  • Chronic weight management (approved indication)
  • Obstructive sleep apnoea in adults with obesity
  • Heart failure with preserved ejection fraction
  • Metabolic dysfunction-associated steatohepatitis

These are research directions reported in the literature, not established effects or recommendations.

Risks, limitations and unknowns

Read this section before the rest

  • Gastrointestinal adverse events are the most frequent reason for discontinuation in trials
  • Boxed warning for thyroid C-cell tumours based on rodent data; contraindicated with personal or family history of medullary thyroid carcinoma or MEN2
  • Pancreatitis, gallbladder disease and, more rarely, severe gastroparesis have been reported
  • Lean-tissue changes are a discussed limitation in the published literature, with limited trial evidence on mitigation
  • Outcome details are reported in the cited peer-reviewed literature.

Evidence ratings

Laboratory studies

Strong

Dual-receptor pharmacology well characterised.

Animal studies

Strong

Consistent additive effects over GLP-1 alone.

Human studies

Strong

Large Phase 3 programme across multiple indications.

Long-term safety

Moderate

Multi-year trial data available; decades-scale data is not.

Comparisons

RT vs TZ

TZ vs SM

References

  1. [1]The pivotal 72-week obesity trial obesity trial — PubMed / NEJM, 2022
  2. [2]The 2021 diabetes head-to-head trial head-to-head with SM — PubMed / NEJM, 2021
  3. [3]The sleep-apnoea trial sleep apnoea — PubMed / NEJM, 2024
  4. [4]Registered TZ trials — ClinicalTrials.gov, current
  5. Reference links open searches and records on PubMed and ClinicalTrials.gov so that every statement above can be traced to primary literature.

Frequently asked questions

What is TZ?+

A once-weekly dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.

Is TZ FDA approved?+

A pharmaceutical form exists in some jurisdictions. The compound supplied by Regena is a research reference material only and is not a licensed medicine.

Why does adding GIP help?+

GIP receptor activation adds insulinotropic effect and appears to improve how adipose tissue handles lipid, and may reduce nausea burden via central signalling.

What are the common side effects?+

Nausea, diarrhoea, vomiting, constipation and reduced appetite, generally dose-related and most pronounced during escalation.

Who should not take TZ?+

It carries a boxed warning for thyroid C-cell tumours and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2. This is a clinical decision, not a self-assessment.

Is TZ a peptide?+

Yes — a 39–amino-acid synthetic peptide with a fatty acid modification.

Share

Continue your research

RT research

SM research

Incretin mechanisms of action

More research reading

Research supply · Independent documentation and customer feedback

We accept · Multiple secure payment methods

  • Bank Transfer
  • Card via Revolut